Clinical Trials Logo
  1. Home
  2. SBRT
  3. NCT06219980

SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx

SBRT Clinical Trial

Official title:
A Phase II Study of SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx

Clinical Trial Summary

In resectable locally advanced oral cavity cancer and oropharyngeal cancer, SBRT with the total dose of 18 Gy by three fractions will be delivered to the primary tumor and metastatic lymph nodes every other day. One week later, neoadjuvant chemoimmunotherapy of Sindilizumab (200mg) plus docetaxel (75mg/m2) and cisplatin (75mg/m2) will be administered every three weeks for three cycles. Then radical surgical resection will be performed and postoperative radiotherapy with or without chemotherapy will be supplemented according to the initial tumor staging and postoperative pathologic characteristics. The investigators aim to evaluate the pathological complete response rate and safety of the combined treatment of SBRT with chemoimmunotherapy in locally advanced cancers of oral cavity and oropharynx.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06219980
Study type Interventional
Source Sun Yat-sen University
Contact Fang-Yun Xie
Phone +862087342926
Email xiefy@sysucc.org.cn
Status Recruiting
Phase Phase 2
Start date December 7, 2023
Completion date December 7, 2026
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04476797 - Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC Phase 1/Phase 2
Not yet recruiting NCT04587817 - Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive Tumors
Active, not recruiting NCT04067570 - Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients With Localized Prostate Cancer N/A
Recruiting NCT02976402 - Stereotactic Hypofractionated Accelerated Radiotherapy Post-Prostatectomy Phase 1
Not yet recruiting NCT02940990 - SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations Phase 2
Terminated NCT04698915 - Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer Phase 2
Active, not recruiting NCT05817604 - Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)
Active, not recruiting NCT04942275 - Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy Phase 2/Phase 3
Recruiting NCT04547452 - Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC Phase 2
Completed NCT03891472 - Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer Phase 2
Recruiting NCT05344235 - Observational Study on Extreme Hypofractionation for Localized Prostate Cancer